Boehringer Ingelheim | sciencenewsnet.in

Breaking News

Curious by Nature: Dr. Neil Johnson – Hate Groups After Elections

Distinguished Lecture by Nobel Laureate, Prof. Jean-Marie Lehn

Distinguished Lecture: Targeting a World-Leading Market Supplier of Graphene Materials

University of Idaho researcher uncovers surprising way to stop beer from exploding

Cedars-Sinai Experts Available to Discuss Healthy Aging During GSA 2024

Novel Pulmonary Valve Aims to Reduce Invasive Surgeries for Kids

When countries hide their true public debt, they hurt themselves, their citizens and their lenders

UTEP Team to Investigate Climate Change Impact on Pecan Orchards

Houston Methodist Tuberculosis expert Ed Graviss says U.S. experiencing its highest number of TB cases in 10 years

أوصى باحثو مايو كلينك ببدائل لاستئصال الرحم لعلاج الأورام الليفية في الرحم، وفقًا لدراسة

08 Nov, 2024

MD Anderson and Boehringer Ingelheim expand collaboration to accelerate development of KRAS and TRAILR2 compounds in lung cancer

April 14, 2021 sarah JonasAnnouncement

MD Anderson and Boehringer Ingelheim have expanded their joint Virtual Research and Development Center to accelerate the development of new targeted therapies against KRAS and TRAILR2 in lung cancer.